Prestwick Pharmaceuticals

Washington, United States Founded: 2002 • Age: 24 yrs Acquired By Biovail
Small molecule drugs for chronic CNS diseases are developed.
Annual revenue - Latest available
Total funding $103.8M 6 rounds
Employees - Tracked headcount
Investors 8 Known backers
Products 4 Services tracked
Competitors - Brand Intelligence

About Prestwick Pharmaceuticals

Prestwick Pharmaceuticals is a company based in Washington (United States) founded in 2002 was acquired by Biovail in September 2008. Prestwick Pharmaceuticals has raised $103.79 million across 6 funding rounds from investors including Warburg Pincus, FirstMark and Atlas Venture. Prestwick Pharmaceuticals offers products and services including Antibodies, Assay Kits, ELISA Kits, and PCR Kits.

  • Headquarter Washington, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $103.79 M (USD)

    in 6 rounds

  • Latest Funding Round
    $20 M (USD), Series C

    Aug 27, 2007

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Biovail

    (Sep 17, 2008)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Prestwick Pharmaceuticals

Prestwick Pharmaceuticals offers a comprehensive portfolio of products and services, including Antibodies, Assay Kits, ELISA Kits, and PCR Kits.

Product name locked
Category locked
Primary

Used for detecting specific proteins in research and diagnostics.

Product name locked
Category locked
Locked

Kits for testing biological samples in various assays.

Product name locked
Category locked
Locked

Tools for enzyme-linked immunosorbent assays in disease detection.

Product name locked
Category locked
Locked

Kits for polymerase chain reaction in DNA amplification.

Funding Insights of Prestwick Pharmaceuticals

Prestwick Pharmaceuticals has successfully raised a total of $103.79M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in August 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Prestwick Pharmaceuticals

Prestwick Pharmaceuticals has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Warburg Pincus, FirstMark and Atlas Venture.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm investing in life science and biotechnology sectors
Locked Locked Locked
Early-stage venture capital is invested in tech startups across sectors.
Locked Locked Locked
Early-stage venture capital investments are focused on US companies.
Locked Locked Locked
Premium access

Investor details for Prestwick Pharmaceuticals

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Prestwick Pharmaceuticals

Investments
Premium access

Investment portfolio details for Prestwick Pharmaceuticals

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Prestwick Pharmaceuticals

Premium access

Detailed financials for Prestwick Pharmaceuticals

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Prestwick Pharmaceuticals Comparisons

Prestwick Pharmaceuticals Primary company
Description
Small molecule drugs for chronic CNS diseases are developed.
Location
Washington, United States
Founded Year
2002
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Prestwick Pharmaceuticals

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Prestwick Pharmaceuticals

Premium access

Detailed competitors of Prestwick Pharmaceuticals

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Prestwick Pharmaceuticals

Premium access

Complete news archive for Prestwick Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Prestwick Pharmaceuticals

Prestwick Pharmaceuticals was founded in 2002 and raised its 1st funding round 1 year after it was founded.

Prestwick Pharmaceuticals is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.

Prestwick Pharmaceuticals is a funded company, having raised a total of $103.79M across 6 funding rounds to date.

Prestwick Pharmaceuticals was founded in 2002 as a specialty pharmaceutical company focused on the development and commercialization of small molecule drugs targeting chronic central nervous system diseases. Operations included early-stage products such as Lisuride for Parkinsons disease and D-Serine for schizophrenia. An exclusive U.S. commercialization agreement for Xenazine in Huntingtons disease was established with Ovation Pharmaceuticals. The company was acquired by Biovail Corp. in September 2008.

Prestwick Pharmaceuticals offers Antibodies, Assay Kits, ELISA Kits, and PCR Kits.

Prestwick Pharmaceuticals has 8 investors. Key investors include Warburg Pincus, FirstMark, Atlas Venture, Biovail, and Scale Venture Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available